Last updated: March 11, 2026
What is NDC 21922-0072?
NDC 21922-0072 corresponds to Omacetaxine Mepesuccinate (Ceplene), a drug used chiefly as a treatment for certain forms of leukemia. It functions as a protein synthesis inhibitor, primarily targeting breakthrough or refractory chronic myeloid leukemia (CML). Its approved indication varies by jurisdiction, with notable approval in the United States and Europe.
Market Position and Therapeutic Landscape
Omacetaxine Mepesuccinate operates within the niche segment of leukemia therapeutics, competing primarily with tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib. It is often used in cases where patients develop resistance or intolerance to TKIs.
Key Market Dynamics:
- Patient Population: Estimated 20,000-25,000 CML patients in the U.S. (2023), with 10-15% developing resistance to TKIs, qualifying for Omacetaxine.
- Regulatory Status:
- FDA approval (2012, accelerated for resistant CML).
- EMA approval for similar indications.
- Market Entry:
- Initially launched as a specialty drug.
- Limited competition due to narrow indication.
Market Size (Prevalence & Incidence):
| Metric |
Data |
Source |
| Estimated CML patients (US) |
20,000-25,000 |
American Cancer Society [1] |
| Resistant/Intolerant Patients |
~3,000-4,000 (15% of total) |
Based on incidence rates [2] |
| TKI-resistant cases |
1,800-2,400 in the US |
Derived from resistance rates |
Historical Pricing and Sales Data
- Average Wholesale Price (AWP):
- Reported at approximately $16,000 for a typical vial (10 mg).
- Annual Sales (2022-2023):
- Estimated at $70-100 million in the US.
- Sales heavily dependent on physician adoption and approval extensions.
Competitive and Regulatory Factors
- Limited direct competitors; primary competitors are alternative TKI therapies and potential emerging drugs.
- Expansions into earlier lines of treatment face regulatory and clinical hurdles.
- Patent status data shows exclusivity through primary patents expiring around 2030.
Price Projections
Short-term (Next 1-2 years):
- Prices are projected to stay stable, with minimal fluctuation.
- Potential price increases driven by inflation and supply chain costs.
- Market penetration rate expected to stabilize around 30-50% among eligible resistant CML patients.
Long-term (3-5 years):
- Price stabilization or slight increase (~3-5%) based on inflation and market expansion.
- Introduction of biosimilars unlikely within that period due to complex manufacturing.
- New indications or expanded approved uses could boost price and sales.
Revenue Estimation (Next 5 Years):
| Year |
Estimated US Sales (USD millions) |
Assumptions |
| 2024 |
75-125 |
Stable market share; minor price increase |
| 2025 |
80-130 |
Slight growth; expanded use considerations |
| 2026 |
85-140 |
Continued market penetration |
| 2027 |
90-150 |
New clinician adoption; price adjustments |
| 2028 |
95-160 |
Maturation of market |
Market Access and Reimbursement Trends
- Reimbursement largely covers branded formulations in major markets.
- PBMs and payers may negotiate discounts or implement utilization management.
- Patients face high out-of-pocket costs, influencing adherence.
Geographic Considerations
- US market constitutes ~80% of sales.
- European markets show similar incidence but with price discounts (~20-30%) due to regional pricing policies.
- Asian markets are emerging but face barriers due to regulatory and economic factors.
Key Takeaways
- NDC 21922-0072 (Omacetaxine Mepesuccinate) remains a niche but critical therapy for resistant CML.
- Current market size is approximately $70-100 million annually, with stable growth.
- Price projections indicate stability with modest growth through 2028, driven by inflation, market expansion, and possible early indications for broader use.
- Competition remains limited, but emerging therapies and biosimilars could influence future pricing.
FAQs
1. Is the price of Omacetaxine Mepesuccinate expected to increase significantly?
Prices are projected to increase marginally (~3-5%) annually, with no major increases expected in the next two years.
2. How many patients could potentially benefit from NDC 21922-0072 in the future?
Approximately 1,800-2,400 patients in the US are resistant or intolerant to TKIs, representing the eligible population.
3. What factors could influence the drug’s market share?
Regulatory expansion, clinical evidence supporting earlier line use, and competition from emerging therapies.
4. Are biosimilars a threat to the current market?
Biosimilars are unlikely within the next 3-5 years due to manufacturing complexity and patent protections.
5. How do regional pricing policies affect potential revenue?
Pricing in Europe and Asia is generally lower, reducing global revenue potential compared to the US market.
References
- American Cancer Society. (2023). Key statistics for leukemia. Retrieved from https://cancer.org
- National Cancer Institute. (2023). Chronic Myeloid Leukemia statistics. https://cancer.gov/about-cancer/diagnosis-staging/types
- IQVIA. (2023). Physician reports and drug price data.
